News Contact Us

Kodak share soars post active drug ingredient development deal

Author : Saipriya Iyer | Published Date : 2020-07-30 

Shares of Eastman Kodak, an American technology company, have recently increased, following the announcement of a deal by the U.S. President Donald Trump. The agreement is regarding the President’s collaboration with the company to produce active ingredients for generic medicines to fight against the deadly COVID-19 disease.

In the extended trading, the shares of Kodak have soared by more than 318%, to nearly $25.26 per share. The U.S. government has offered a $765 million loan to the company to commence the production of ingredients for the generic drugs, under the Defense Production Act.

The U.S. president has reportedly stated that the country’s 33rd adoption of the Defense Production Act will mobilize Kodak in manufacturing active pharmaceutical ingredients. This will also aid America in becoming the premier medical supplier and manufacturer.

The photography company has cited that it will provide essential pharmaceutical components to meet the chronic shortages in the nation, as defined by the U.S. FDA. The recent 1,300% increase in the stock price has recently enabled it to record a market capitalization of over $1.5 billion. Prior to this, the company registered a value of nearly $115 million.

To ensure rapid production, Kodak will expand its existing facilities in St. Paul, Minnesota, New York, and Rochester, under a new arm of Kodak Pharmaceuticals.

As per the statement made by Jim Continenza, Executive Chairman of Kodak, the company is excited to play a key role in strengthening the country’s self-sufficiency by offering major ingredients in the U.S. It will leverage its heritage in quality and innovation, deep expertise in chemicals production, and vast infrastructure to advance America as a reliable pharmaceutical supply chain.

In 2012, the company had filed for bankruptcy due to the shifting consumer preferences to digital cameras. The recent deal to enter the drug production business will present a significant growth opportunity for the company.

Source credit:

About Author

Saipriya Iyer

Saipriya Iyer

Saipriya Iyer presently works as a content developer for fractovia.org. Having dabbled with the domain of content creation for nearly half a decade, she now boasts of an enviable portfolio, holding substantial experience in penning down pieces related to technology, finance, and a wide spectrum of other industry verticals. A qualified computer engineering graduate from the University of Pune, Saipriya can often be found leveraging her knowledge of software technology and electronics in her write-ups. She can be contacted at- [email protected] | https://twitter.com/saipriya_i

Related News

India readies 5 sites for Phase 3 Oxford-AstraZeneca vaccine trial

Published Date: 2020-07-29         Author: Saipriya Iyer

Phase 3 or late-stage clinical trial of the Oxford-AstraZeneca coronavirus vaccine is reportedly set to be conducted across 5 sites in India. Additionally, Oxford and its partner, AstraZeneca, have chosen the Serum Institute of India to manufacture the COVID-19 vaccine, following the anticipated ... Read More

Huawei lays off staffs in India amid calls to boycott Chinese products

Published Date: 2020-07-28         Author: Saipriya Iyer

Huawei Technologies Co., a telecommunications equipment company, has reportedly reduced its revenue target for 2020 in India by over 50%. Additionally, the multinational technology company is laying off more than half the capacity of its employees in the country. The decision has been made amid t... Read More

UK banks developing code of conduct on defaulting business loans

Published Date: 2020-07-07         Author: Saipriya Iyer

UK banks are reportedly developing a code of conduct for businesses who have defaulted on the coronavirus loans which are taxpayer-backed. According to industry estimates, around 8 out of 10 borrowers may not be able to repay the loans in full amount. UK Finance and British Business Bank were rep... Read More

© 2020 Fractovia. All Rights Reserved